José Trevejo M.D. Ph.D Appointed Chief Medical Office at Enveda Biosciences

Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today the appointment of José Trevejo M.D. Ph.D., as Chief Medical Officer and Head of Clinical Pipeline Strategy. In this role, Dr. Trevejo will lead the clinical organization and oversee the advancement of Enveda’s robust pipeline that spans multiple therapeutic areas.

Dr. José Trevejo joins Enveda following a string of recent successes, most recently at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of a novel category-creating ophthalmic treatment along with multiple positive Phase 2 readouts. He brings more than fifteen years of leadership and drug development expertise to Enveda, spanning the entire clinical development process from proof-of-concept through approval and early commercialization. Dr. Trevejo has worked across numerous therapeutic areas, including GI, dermatology, ophthalmology, infectious disease, cardiac and metabolic disease as well as immunology.

“We are incredibly excited to welcome Dr. José Trevejo to our leadership team,” said Viswa Colluru, Ph.D., CEO and Founder of Enveda. “His entrepreneurial spirit is further complemented by the operational excellence that he learned from his time at Vertex, Genentech and other successful biopharma companies. His deep background in shepherding novel therapies successfully through clinical trials will be essential to Enveda’s success as we prepare our first two drug candidates for transition into human clinical trials, with many more close behind.”

“It is a huge honor to be joining Enveda at this transformative phase of the company,” says Dr. Trevejo. “Enveda’s approach to identifying new molecules from nature using AI and then adapting them into novel medicines is compelling. However, Enveda’s platform offers more than just a technological breakthrough in identifying novel chemical entities, as the drug candidates in Enveda’s pipeline have the potential to address high impact diseases for patients across a range of therapeutic areas. I believe Enveda’s approach will potentially offer new hope to these patients, and I am excited by the opportunity to contribute to such an innovative company and culture that represents the cutting edge of drug discovery and development.”

José Trevejo M.D., Ph.D. is a physician-scientist and biotechnology executive who has led organizations in the development of high impact medicines spanning multiple therapeutic areas. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr.Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Jose held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Jose Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.